Back to top
more

RELYPSA INC (RLYP)

(Delayed Data from NSDQ)

$31.99 USD

31.99
2,430,289

+0.02 (0.06%)

Updated Aug 31, 2016 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

[RLYP]

Reports for Purchase

Showing records 1 - 20 ( 113 total )

Industry: Medical - Generic Drugs

Record: 1

09/01/2016

Daily Note

Pages: 44

September and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 2

09/01/2016

Company Report

Pages: 6

Downgrading Our Rating to NEUTRAL and Reducing Our Price Target to $32 as Tender Offer Close to Completion

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 3

08/19/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 4

08/05/2016

Company Report

Pages: 6

Q2 Financials Were Uneventful; We Continue to Believe the Value of Veltassa Supports a Higher Bid

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 5

08/01/2016

Daily Note

Pages: 46

August and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 6

07/22/2016

Company Report

Pages: 5

Galenica Acquires Relypsa; Offer Price Matches Our PT; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 7

07/21/2016

Daily Note

Pages: 7

Relypsa (RLYP - OUTPERFORM): Relypsa and Galenica Agree to $32 per Share Acquisition; Reiterate OUTPERFORM and $51 Price Target As We See Room for Another Bidder.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 8

07/12/2016

Company Report

Pages: 7

Veltassa Script Growth Accelerates in June; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 9

07/11/2016

Daily Note

Pages: 6

June Prescription Figures Point to Steady Growth; Reiterate OUTPERFORM and $51 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 10

07/01/2016

Industry Report

Pages: 46

July and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 11

06/17/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 12

06/15/2016

Daily Note

Pages: 6

May Prescription Figures Point to Continued Uptake;Reiterate OUTPERFORM and $51 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 13

06/10/2016

Daily Note

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 14

06/08/2016

Daily Note

Pages: 6

KOL Nephrologist Considers Veltassa to be Best-In- Class Among Hyperkalemia Treatments; Reiterate OUTPERFORM and $51 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 15

06/03/2016

Daily Note

Pages: 5

We See Improving Investor Sentiment Post ZS-9 CRL; Reiterate OUTPERFORM and $51 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 16

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 17

05/31/2016

Daily Note

Pages: 3

ZS-9 Loses its Halo: CRL Cites Manufacturing Issues

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 18

05/27/2016

Daily Note

Pages: 5

ZS-9 Received a CRL Which Strengthens Veltassa''s Commercial Potential in Our View; Reiterate OUTPERFORM and $51 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 19

05/18/2016

Company Report

Pages: 7

April Prescriptions Reflect Physicians Testing Veltassa Prior to Widespread Change of Practice

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Generic Drugs

Record: 20

05/17/2016

Daily Note

Pages: 3

Veltassa New Starts Growth Pauses in April; Affirm Buy on Expected Weakness

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

// eof